Impact Biomedical (IBO) Return on Capital Employed (2023 - 2026)
Impact Biomedical (IBO) posted Return on Capital Employed of 34.71% for Q1 2026, down 106.1% on a QoQ basis from 568.75% in Q3 2025, and up 24962.0% year-over-year from N/an in Q1 2025.
Impact Biomedical (IBO) Return on Capital Employed (2023 - 2026) Analysis & Trends
Impact Biomedical's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 34.71% for Q1 2026.
- Quarterly Return on Capital Employed rose 24962.0% year-over-year to 34.71% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.71% (up 24962.0% YoY) and the FY2024 annual result came in at 126.8%, down 11438.0% from the prior year.
- Return on Capital Employed was 34.71% for Q1 2026 at Impact Biomedical, down from 568.75% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 816.29% in Q2 2025 and bottomed at 284.32% in Q1 2025.
- A 4-year average of 88.68% and a median of 12.43% in 2023 frame the typical range for Return on Capital Employed.
- Peak annual rise in Return on Capital Employed reached 82844 bps in 2025, while the deepest fall reached 27128 bps in 2025.
- Impact Biomedical's Return on Capital Employed stood at 12.7% in 2023, then plunged by 855 bps to 121.29% in 2024, then jumped by 569 bps to 568.75% in 2025, then plunged by 106 bps to 34.71% in 2026.
- Business Quant data shows IBO's Return on Capital Employed at 34.71% in Q1 2026, 568.75% in Q3 2025, and 816.29% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Impact Biomedical | 47.44 Mn | 50.67 Mn | - | -34.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.71% |
| Sep 30, 2025 | 568.75% |
| Jun 30, 2025 | 816.29% |
| Mar 31, 2025 | -284.32% |
| Dec 31, 2024 | -121.29% |
| Sep 30, 2024 | -8.27% |
| Jun 30, 2024 | -12.15% |
| Mar 31, 2024 | -13.04% |
| Dec 31, 2023 | -12.70% |
| Sep 30, 2023 | -11.79% |